CLDX
Celldex Therapeutics Inc.
$24.86
+$0.25(+1.02%)
45
Overall
--
Value
45
Tech
--
Quality
Market Cap
$1.63B
Volume
1.01M
52W Range
$14.40 - $47.00
Target Price
$55.69
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $5.5M | $6.8M | $12.7M | $9.5M | $3.6M | $7.4M | $4.7M | $2.4M | $6.9M | $7.0M | ||
| Total Revenue | $5.5M | $6.8M | $12.7M | $9.5M | $3.6M | $7.4M | $4.7M | $2.4M | $6.9M | $7.0M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | $-1.6M | $-700.0K | $-700.0K | $100.0K | $200.0K | $100.0K | $100.0K | $300.0K | $200.0K | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $5.5M | $6.8M | $12.7M | $9.5M | $3.6M | $7.4M | $4.7M | $2.4M | $6.9M | $7.0M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $135.0M | $139.7M | $122.1M | $85.9M | $58.1M | $57.0M | $73.8M | $109.5M | $148.9M | $202.1M | ||
| Research & Development | $100.2M | $102.7M | $96.2M | $66.4M | $42.7M | $42.5M | $53.3M | $82.3M | $118.0M | $163.6M | ||
| Research Expense | $100.2M | $102.7M | $96.2M | $66.4M | $42.7M | $42.5M | $53.3M | $82.3M | $118.0M | $163.6M | ||
| Selling, General & Administrative | $33.8M | $36.0M | $25.0M | $19.3M | $15.4M | $14.5M | $20.5M | $27.2M | $30.9M | $38.5M | ||
| General & Administrative Expenses | $33.8M | $36.0M | $25.0M | $19.3M | $15.4M | $14.5M | $20.5M | $27.2M | $30.9M | $38.5M | ||
| Salaries & Wages | $-12.8M | -- | -- | -- | $-4.6M | $-3.9M | $-9.0M | -- | $23.9M | $34.2M | ||
| Depreciation & Amortization | $1.0M | $997.0K | $896.0K | $224.0K | $4.9M | $3.9M | $3.1M | $2.9M | $3.0M | $3.2M | ||
| Depreciation & Amortization | $1.0M | $997.0K | $896.0K | $224.0K | $4.9M | $3.9M | $3.1M | $2.9M | $3.0M | $3.2M | ||
| Amortization | $1.0M | $997.0K | $896.0K | $224.0K | -- | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | $-4.0M | $2.5M | $2.3M | $1.9M | $1.9M | $1.9M | $2.0M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-129.5M | $-132.9M | $-109.3M | $-76.4M | $-55.0M | $-63.4M | $-71.2M | $-115.2M | $-154.5M | $-195.1M | ||
| EBITDA | $-122.5M | $-121.9M | $-112.3M | $-149.2M | $-47.2M | $-45.6M | $-66.1M | $-104.2M | $-174.5M | $-194.5M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Intinc | $2.3M | $4.4M | $4.2M | $4.5M | $4.2M | $2.4M | $505.0K | $2.9M | $13.1M | $37.2M | ||
| Net Non-Operating Interest Income/Expense | $2.3M | $4.4M | $4.2M | $4.5M | $4.2M | $2.4M | $505.0K | $2.9M | $13.1M | $37.2M | ||
| Other Income/Expense | $-1.0M | $-2.8M | $-800.0K | $-10.9M | $506.0K | $13.8M | $2.1M | $-5.2M | $613.0K | $-3.1M | ||
| Other Special Charges | -- | -- | -- | -- | $1.4M | $200.0K | $3.4M | $400.0K | $100.0K | $3.1M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | $-13.0M | $-91.0M | -- | -- | -- | $-15.0M | $-12.5M | -- | ||
| Impairment of Capital Assets | -- | -- | $13.0M | $91.0M | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-127.2M | $-128.5M | $-117.3M | $-151.9M | $-50.9M | $-49.6M | $-69.1M | $-107.1M | $-177.5M | $-197.7M | ||
| Pre-Tax Income | $-127.2M | $-128.5M | $-117.3M | $-151.9M | $-50.9M | $-60.9M | $-70.7M | $-112.3M | $-141.4M | $-157.9M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-1.6M | $-2.1M | $-24.3M | $-765.0K | $-13.9M | $-1.2M | $-227.0K | $-17.5M | $-36.1M | $-39.8M | ||
| NET INCOME | ||||||||||||
| Net Income | $-127.2M | $-128.5M | $-93.0M | $-151.2M | $-50.9M | $-59.8M | $-70.5M | $-112.3M | $-141.4M | $-157.9M | ||
| Net Income (Continuing Operations) | $-127.2M | $-128.5M | $-93.0M | $-151.2M | $-50.9M | $-59.8M | $-70.5M | $-112.3M | $-141.4M | $-157.9M | ||
| Net Income (Discontinued Operations) | $-127.2M | $-128.5M | $-93.0M | $-151.2M | $-50.9M | $-59.8M | $-70.5M | $-112.3M | $-141.4M | $-157.9M | ||
| Net Income (Common Stockholders) | $-127.2M | $-128.5M | $-93.0M | $-151.2M | $-50.9M | $-59.8M | $-70.5M | $-112.3M | $-141.4M | $-157.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-197.7M | ||
| TOTALS | ||||||||||||
| Total Expenses | $135.0M | $138.1M | $121.4M | $85.2M | $58.2M | $57.2M | $73.9M | $109.5M | $149.2M | $202.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $6.5M | $6.8M | $8.6M | $696.1K | $14.5M | $29.6K | $42.9K | $46.9K | $48.4K | $64.4K | ||
| Average Shares Outstanding (Diluted) | $6.5M | $6.8M | $8.6M | $696.1K | $14.5M | $29.6K | $42.9K | $46.9K | $48.4K | $64.4K | ||
| Shares Outstanding | $6.6M | $8.2M | $9.4M | $829.3K | $17.6M | $39.6M | $46.7M | $47.2M | $55.9M | $66.4M | ||
| Basic EPS | -- | $-19.05 | $-10.8 | $-217.2 | -- | -- | $-1.64 | $-2.4 | $-2.92 | $-2.45 | ||
| Basic EPS (Continuing Operations) | -- | $-19.05 | $-10.8 | $-217.2 | -- | -- | -- | $-2.4 | $-2.92 | $-2.45 | ||
| Diluted EPS | $-19.65 | $-19.05 | $-10.8 | $-217.2 | $-3.51 | $-2.02 | $-1.64 | $-2.4 | $-2.92 | $-2.45 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-3.51 | $-2.02 | -- | $-2.4 | $-2.92 | $-2.45 | ||
| OTHER METRICS | ||||||||||||
| Acquisition Expense | -- | $-700.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | $1.0M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | -- | -- | -- | -- | -- | -- | -- | $15.0M | $12.5M | -- | ||
| Other Gand A | $33.8M | $36.0M | $25.0M | $19.3M | $15.4M | $14.5M | $20.5M | $27.2M | $30.9M | $38.5M | ||
| Other Impairment Of Capital Assets | -- | -- | $-13.0M | $18.7M | $1.8M | $18.0M | $3.5M | -- | -- | -- | ||
| Rent And Landing Fees | $33.8M | $-4.8M | -- | -- | -- | -- | $20.5M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CLDX | $24.86 | +1.0% | 1.01M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Celldex Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW